Dissemin is shutting down on January 1st, 2025

Published in

Taylor and Francis Group, OncoImmunology, 12(2), p. e27214

DOI: 10.4161/onci.27214

Links

Tools

Export citation

Search in Google Scholar

Acute myeloid leukemia therapeutics

Journal article published in 2013 by Armen Mardiros, Christine E. Brown, L. Elizabeth Budde, Xiuli Wang ORCID, Stephen J. Forman
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Acute myeloid leukemia remains a difficult disease to cure and novel therapeutic approaches are needed. To this end, we developed CD123 chimeric antigen receptor (CAR) redirected T cells which exhibited potent antileukemic activity. We discuss what we learned during the development of CD123 CARs and future directions for this immunotherapy.